Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease
暂无分享,去创建一个
Jon Hainer | Nishant R. Shah | Sharmila Dorbala | N. Cook | L. Shaw | R. Blankstein | V. Murthy | M. D. Di Carli | S. Dorbala | J. Hainer | C. Foster | V. Taqueti | Ron Blankstein | Leslee J. Shaw | Marcelo F. Di Carli | Viviany R. Taqueti | Nancy R. Cook | Venkatesh L. Murthy | Nishant R. Shah | Courtney R. Foster | N. Shah
[1] Robert Califf,et al. Value of the History and Physical in Identifying Patients at Increased Risk for Coronary Artery Disease , 1993, Annals of Internal Medicine.
[2] F. Harrell,et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. , 1994, Circulation.
[3] James T. Willerson,et al. Appointment of New Associate Editor for Circulation , 1996 .
[4] J. Willerson. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, Circulation.
[5] Robert L. Frye,et al. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.
[6] R. Virmani,et al. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. , 1998, Circulation.
[7] O Muzik,et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. , 1999, Circulation.
[8] M. Cerqueira,et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.
[9] D. Berman,et al. Comparison of the Short‐Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery Disease Undergoing Stress Myocardial Perfusion Single Photon Emission Computed Tomography , 2003, Circulation.
[10] K. Smith,et al. Abnormal Coronary Vasomotion as a Prognostic Indicator of Cardiovascular Events in Women: Results From the National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE) , 2004, Circulation.
[11] Carl J Pepine,et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. , 2006, Journal of the American College of Cardiology.
[12] Georges El Fakhri,et al. Reproducibility and Accuracy of Quantitative Myocardial Blood Flow Assessment with 82Rb PET: Comparison with 13N-Ammonia PET , 2009, Journal of Nuclear Medicine.
[13] Carl J Pepine,et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. , 2009, Archives of internal medicine.
[14] C. Noel Bairey Merz,et al. Women and ischemic heart disease: evolving knowledge. , 2009, Journal of the American College of Cardiology.
[15] Oliver Gaemperli,et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. , 2009, Journal of the American College of Cardiology.
[16] Antonio Colombo,et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.
[17] Maria Mori Brooks,et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.
[18] S. Kelsey,et al. A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). , 2010, American heart journal.
[19] P. Libby,et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.
[20] B. Borlaug,et al. Why are women more likely than men to develop heart failure with preserved ejection fraction? , 2011, Current opinion in cardiology.
[21] M. Pencina,et al. Improved Cardiac Risk Assessment With Noninvasive Measures of Coronary Flow Reserve , 2011, Circulation.
[22] J. Hochman,et al. Women have less severe and extensive coronary atherosclerosis in fatal cases of ischemic heart disease: an autopsy study. , 2011, American heart journal.
[23] M. Javadi,et al. Prediction of Short-Term Cardiovascular Events Using Quantification of Global Myocardial Flow Reserve in Patients Referred for Clinical 82Rb PET Perfusion Imaging , 2011, The Journal of Nuclear Medicine.
[24] Kathryn A. Williams,et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. , 2011, Journal of the American College of Cardiology.
[25] R. Blankstein,et al. Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients With and Without Diabetes Mellitus , 2012, Circulation.
[26] S. Solomon,et al. Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease , 2012, Circulation.
[27] Akshay S. Desai,et al. Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.
[28] W. Paulus,et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.
[29] Juhani Knuuti,et al. Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. , 2013, Journal of the American College of Cardiology.
[30] O. Rimoldi,et al. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. , 2013, JACC. Cardiovascular imaging.
[31] M. Shishehbor,et al. Strategies for multivessel revascularization in patients with diabetes , 2013 .
[32] P. Libby,et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. , 2013, American heart journal.
[33] F. Rybicki,et al. Prognostic Value of Nonobstructive and Obstructive Coronary Artery Disease Detected by Coronary Computed Tomography Angiography to Identify Cardiovascular Events , 2014, Circulation. Cardiovascular imaging.
[34] C. B. Bairey Merz. Sex, death, and the diagnosis gap. , 2014, Circulation.
[35] C. N. Merz. Sex, Death, and the Diagnosis Gap , 2014 .
[36] O. Rimoldi,et al. Effects of Sex on Coronary Microvascular Dysfunction and Cardiac Outcomes , 2014, Circulation.
[37] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[38] R. Blankstein,et al. Interaction of Impaired Coronary Flow Reserve and Cardiomyocyte Injury on Adverse Cardiovascular Outcomes in Patients Without Overt Coronary Artery Disease , 2015, Circulation.
[39] M. Walsh,et al. Emergence of Nonobstructive Coronary Artery Disease: A Woman's Problem and Need for Change in Definition on Angiography. , 2015, Journal of the American College of Cardiology.
[40] R. Blankstein,et al. Global Coronary Flow Reserve Is Associated With Adverse Cardiovascular Events Independently of Luminal Angiographic Severity and Modifies the Effect of Early Revascularization , 2015, Circulation.
[41] E. Braunwald. The war against heart failure: the Lancet lecture , 2015, The Lancet.
[42] M. Jessup,et al. "Frailty, thy name is woman": syndrome of women with heart failure with preserved ejection fraction. , 2015, Circulation. Cardiovascular quality and outcomes.
[43] Jennifer G. Robinson,et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.
[44] K. Rexrode,et al. Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association. , 2015, Circulation.
[45] Ryotaro Yamada,et al. Invasive Evaluation of Patients With Angina in the Absence of Obstructive Coronary Artery Disease , 2015, Circulation.
[46] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[47] Tyler J VanderWeele,et al. eAppendix for : ” SAS macro for causal mediation analysis with survival data ” , 2014 .
[48] Mark D. Huffman,et al. AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .
[49] D. Berman,et al. Prognostic and Therapeutic Implications of Statin and Aspirin Therapy in Individuals With Nonobstructive Coronary Artery Disease: Results From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter Registry) Registry , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[50] Eric E. Smith,et al. Sex and Race/Ethnicity–Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults , 2016, Circulation. Cardiovascular quality and outcomes.
[51] K. Schenck-Gustafsson,et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. , 2016, European heart journal.